Very Late Thrombosis in Bioresorbable Scaffolds

The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors thrombosis, leaving the vessel vulnerable to very late thrombosis. Dual antiplatelet therapy, a better implantation technique, and several improvements in new drug-eluting stents (DES) (thinner struts, and higher polymer stability and biocompatibility) have lowered significantly the incidence of this event, which is now less than 1% at 1 year. While these outcomes are much better than what they were for first-generation DES, they are still far from being perfect.

Trombosis muy tardía en plataformas bioabsorbibles

Bioresorbable scaffolds were developed while focusing on long-term safety and efficacy. Immediate scaffolding to prevent elastic recoil, sealing dissections, carrying anti-proliferating agents such as everolimus, and subsequent bioresorption so that the artery can go back to its normal anatomy and physiology would theoretically translate in clinical benefit during a long-term follow-up.


Read also: Conscious Sedation in TAVR: Is It Advisable?”


Everolimus-eluting bioresorbable scaffold “Absorb” was found non-inferior to everolimus-eluting stent “Xience” after a 1-year follow-up. However, it also presented higher rates of target-vessel infarction and thrombosis. The promises of “Absorb” should have started to come true after 1 year, which explains the high expectations surrounding this much awaited scientific evidence.

 

This meta-analysis included 5 randomized studies and a total of 1730 patients. It compared Absorb and Xience after a follow-up of at least 24 months. The primary safety endpoint was definite/probable thrombosis.


Read also: Additional Benefit from Radial Artery Graft in Myocardial Revascularization Surgery”.


Patients treated with Absorb had a higher risk of definite/probable thrombosis compared with patients treated with Xience (odds ratio [OR]: 2.93; 95% confidence interval [CI]: 1.37-6.26; p = 0.01). Very late thrombosis occurred in 13/996 patients in the Absorb group (1.4%) vs. 1/701 patients in the Xience group (0.5%). In general, 92% of all cases of very late thrombosis in the Absorb group occurred once dual antiplatelet therapy had been interrupted.

 

Conclusion

Compared with Xience, bioresorbable scaffold Absorb was associated with a higher rate of very late thrombosis, which occurred in 1.4% of all patients.

 

Editorial

Expectations as regards the long-term benefit of bioresorbable scaffolds are completely shot down by the emergence of this evidence.

 

Scaffold thrombosis seems to present a bimodal distribution, with an early peak (<30 days) and a late peak after 1 year. The incidence of thrombosis with Absorb (1.4%) is similar to that presented by first-generation DES such as Taxus, and it is three times the incidence presented by new-generation DES such as Xience. These outcomes prove the falsehood of promises of higher safety, as well as of higher efficacy, since the rates of target-vessel revascularization are significantly higher than for Xience.

 

In that sense, we still do not know if prolonged dual antiplatelet therapy might protect these patients from a risk for very late thrombosis.

 

Original title: Late Thrombotic Events After Bioresorbable Scaffold Implantation: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.

Reference: Carlos Collet et al. European Heart Journal (2017) 0, 1-8. Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...